METHOCARBAMOL - methocarbamol tablet, film coated Aurobindo Pharma Limited


Methocarbamol Tablets, USP

Rx only

DESCRIPTION

Methocarbamol tablets, USP, a carbamate derivative of guaifenesin, is a central nervous system (CNS) depressant with sedative and musculoskeletal relaxant properties.

The chemical name of methocarbamol is 3-(2-methoxyphenoxy)-1,2-propanediol 1-carbamate and has the empirical formula $C_{11}H_{15}NO_5$. Its molecular weight is 241.24. The structural formula is shown below.



Methocarbamol is a white bulky powder, sparingly soluble in water and chloroform, soluble in alcohol only with heating and insoluble in benzene and *n*-hexane.

Methocarbamol tablets USP, 500 mg are available as white in color, round, beveled edge, biconvex film-coated tablet containing 500 mg of methocarbamol USP for oral administration.

Methocarbamol tablets USP, 750 mg are available as white in color, biconvex capsule shaped film-coated tablet containing 750 mg of methocarbamol USP for oral administration.

Methocarbamol tablets USP, 500 mg and 750 mg contain the following inactive ingredients: corn starch, hypromellose, magnesium stearate, polyethylene glycol, povidone, sodium lauryl sulfate, sodium starch glycolate, talc and titanium dioxide.

FDA approved dissolution test specifications differ from USP for 500 mg.

CLINICAL PHARMACOLOGY

The mechanism of action of methocarbamol in humans has not been established, but may be due to general CNS depression. It has no direct action on the contractile mechanism of striated muscle, the motor end plate or the nerve fiber.

Pharmacokinetics

In healthy volunteers, the plasma clearance of methocarbamol ranges between 0.20 and 0.80 L/h/kg, the mean plasma elimination half-life ranges between 1 and 2 hours, and the plasma protein binding ranges between 46% and 50%.

Methocarbamol is metabolized via dealkylation and hydroxylation. Conjugation of methocarbamol also is likely. Essentially all methocarbamol metabolites are eliminated in the urine. Small amounts of unchanged methocarbamol also are excreted in the urine.

Special populations

Elderly

The mean (\pm SD) elimination half-life of methocarbamol in elderly healthy volunteers (mean [\pm SD] age, 69 [\pm 4] years) was slightly prolonged compared to a younger (mean [\pm SD] age, 53.3 [\pm 8.8] years), healthy population (1.5 [\pm 0.4] hours versus 1.1 [\pm 0.27] hours, respectively). The fraction of bound methocarbamol was slightly decreased in the elderly versus younger volunteers (41% to 43% versus 46% to 50%, respectively).

Renally impaired

The clearance of methocarbamol in 8 renally-impaired patients on maintenance hemodialysis was reduced about 40% compared to 17 normal subjects, although the mean (\pm SD) elimination half-life in these two groups was similar: 1.2 (\pm 0.6) versus 1.1 (\pm 0.3) hours, respectively.

Hepatically impaired

In 8 patients with cirrhosis secondary to alcohol abuse, the mean total clearance of methocarbamol was reduced approximately 70% compared to that obtained in 8 ageand weight-matched normal subjects. The mean (\pm SD) elimination half-life in the cirrhotic patients and the normal subjects was 3.38 (\pm 1.62) hours and 1.11 (\pm 0.27) hours, respectively. The percent of methocarbamol bound to plasma proteins was decreased to approximately 40% to 45% compared to 46% to 50% in the normal subjects.

INDICATIONS AND USAGE

Methocarbamol tablets are indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions. The mode of action of methocarbamol has not been clearly identified, but may be related to its sedative properties. Methocarbamol does not directly relax tense

skeletal muscles in man.

CONTRAINDICATIONS

Methocarbamol tablets are contraindicated in patients hypersensitive to methocarbamol or to any of the tablet components.

WARNINGS

Since methocarbamol may possess a general CNS depressant effect, patients receiving methocarbamol should be cautioned about combined effects with alcohol and other CNS depressants.

Safe use of methocarbamol has not been established with regard to possible adverse effects upon fetal development. There have been reports of fetal and congenital abnormalities following in utero exposure to methocarbamol. Therefore, methocarbamol should not be used in women who are or may become pregnant and particularly during early pregnancy unless in the judgment of the physician the potential benefits outweigh the possible hazards (see **PRECAUTIONS, Pregnancy**).

Use in Activities Requiring Mental Alertness

Methocarbamol may impair mental and/or physical abilities required for performance of hazardous tasks, such as operating machinery or driving a motor vehicle. Patients should be cautioned about operating machinery, including automobiles, until they are reasonably certain that methocarbamol therapy does not adversely affect their ability to engage in such activities.

PRECAUTIONS

Information for Patients

Patients should be cautioned that methocarbamol may cause drowsiness or dizziness, which may impair their ability to operate motor vehicles or machinery.

Because methocarbamol may possess a general CNS-depressant effect, patients should be cautioned about combined effects with alcohol and other CNS depressants.

Drug Interactions

See **WARNINGS** and **PRECAUTIONS** for interaction with CNS drugs and alcohol.

Methocarbamol may inhibit the effect of pyridostigmine bromide. Therefore, methocarbamol should be used with caution in patients with myasthenia gravis receiving anticholinesterase agents.

Drug/Laboratory Test Interactions

Methocarbamol may cause a color interference in certain screening tests for 5hydroxyindoleacetic acid (5-HIAA) using nitrosonaphthol reagent and in screening tests for urinary vanillylmandelic acid (VMA) using the Gitlow method.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Long-term studies to evaluate the carcinogenic potential of methocarbamol have not been performed. No studies have been conducted to assess the effect of methocarbamol on mutagenesis or its potential to impair fertility.

Pregnancy

Teratogenic Effects

Animal reproduction studies have not been conducted with methocarbamol. It is also not known whether methocarbamol can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Methocarbamol should be given to a pregnant woman only if clearly needed.

Safe use of methocarbamol has not been established with regard to possible adverse effects upon fetal development. There have been reports of fetal and congenital abnormalities following in utero exposure to methocarbamol. Therefore, methocarbamol should not be used in women who are or may become pregnant and particularly during early pregnancy unless in the judgment of the physician the potential benefits outweigh the possible hazards (see **WARNINGS**).

Nursing Mothers

Methocarbamol and/or its metabolites are excreted in the milk of dogs; however, it is not known whether methocarbamol or its metabolites are excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when methocarbamol is administered to a nursing woman.

Pediatric Use

Safety and effectiveness of methocarbamol in pediatric patients below the age of 16 have not been established.

ADVERSE REACTIONS

Adverse reactions reported coincident with the administration of methocarbamol include:

Body as a whole: Anaphylactic reaction, angioneurotic edema, fever, headache

Cardiovascular system: Bradycardia, flushing, hypotension, syncope, thrombophlebitis

Digestive system: Dyspepsia, jaundice (including cholestatic jaundice), nausea and vomiting

Hemic and lymphatic system: Leukopenia

Immune system: Hypersensitivity reactions

Nervous system: Amnesia, confusion, diplopia, dizziness or lightheadedness, drowsiness, insomnia, mild muscular incoordination, nystagmus, sedation, seizures (including grand mal), vertigo

Skin and special senses: Blurred vision, conjunctivitis, nasal congestion, metallic taste, pruritus, rash, urticaria

OVERDOSAGE

Limited information is available on the acute toxicity of methocarbamol. Overdose of methocarbamol is frequently in conjunction with alcohol or other CNS depressants and includes the following symptoms: nausea, drowsiness, blurred vision, hypotension, seizures, and coma.

In post-marketing experience, deaths have been reported with an overdose of methocarbamol alone or in the presence of other CNS depressants, alcohol or psychotropic drugs.

Treatment

Management of overdose includes symptomatic and supportive treatment. Supportive measures include maintenance of an adequate airway, monitoring urinary output and vital signs, and administration of intravenous fluids if necessary. The usefulness of hemodialysis in managing overdose is unknown.

DOSAGE AND ADMINISTRATION

Methocarbamol tablets, 500 mg - Adults:

Initial dosage: 3 tablets 4 times daily.

Maintenance dosage: 2 tablets 4 times daily.

Methocarbamol tablets: 750 mg - Adults:

Initial dosage: 2 tablets 4 times daily.

Maintenance dosage: 1 tablet q.4h. or 2 tablets 3 times daily.

Six grams a day are recommended for the first 48 to 72 hours of treatment. (For severe conditions 8 grams a day may be administered.) Thereafter, the dosage can usually be reduced to approximately 4 grams a day.

HOW SUPPLIED

Methocarbamol Tablets USP, 500 mg are white in color, round, beveled edge, biconvex film-coated tablet debossed with "500" above the score line on one side and "METT" on the other side. They are supplied as follows:

Bottles of 100	NDC 59651-340-01
Bottles of 500	NDC 59651-340-05

Methocarbamol Tablets USP, 750 mg are white in color, biconvex capsule shaped film-coated tablet, debossed with "METT" on one side and "750" on the other side. They are supplied as follows:

Bottles of 100	NDC 59651-341-01
Bottles of 500	NDC 59651-341-05

Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].

Dispense in tight container.

For more information, call Aurobindo Pharma USA, Inc.at 1-866-850-2876.

Distributed by: **Aurobindo Pharma USA, Inc.** 279 Princeton-Hightstown Road East Windsor, NJ 08520

Manufactured by: **Aurobindo Pharma Limited** Hyderabad-500 032, India

Revised: 08/2022


PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 500 mg (100 Tablets Bottle)

NDC 59651-340-01

Rx only Methocarbamol Tablets, USP 500 mg

AUROBINDO

100 Tablets




PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 750 mg (100 Tablets Bottle)

NDC 59651-341-01

Rx only Methocarbamol Tablets, USP 750 mg

AUROBINDO

100 Tablets



METHOCARBAMOL

methocarbamol t	ablet, film co	ated					
Product Infor	mation						
Product Type		HUMAN PRESCRIPTION DRUG Item Code (Source)				59651-340	
Route of Admini	stration	ORAL					
Active Ingredi	ent/Active	Moietv					
Active mgreat		edient Name		Basis of S	Strenath	Strength	
Methocarbamol (L	-	7X) (Methocarbamol - UNII:12	250D7		-	500 mg	
				·		J	
Inactive Ingre	dients						
indetive ingre	alents	Ingredient Name				Strength	
STARCH, CORN (UI	NII: 08232NY3S	-				enengen	
) (UNII: 0WZ8WG20P6)					
MAGNESIUM STEA							
POLYETHYLENE G	LYCOL 400 (UI	NII: B697894SGQ)					
POVIDONE K30 (U	NII: U725QWY32	X)					
SODIUM LAURYL S							
		(PE A POTATO (UNII: 5856)	3G2A2)			
TALC (UNII: 7SEV7J4							
TITANIUM DIOXIDE	E (UNII: 15FIX9V	2JP)					
Product Chara	acteristics						
Color	WHITE		Scor	e	2 piece	S	
Shape	ROUND (Bi	convex)	Size		13mm		
Flavor		Imprint Code 500;			500;ME	TT	
Contains							
Packaging							
# Item Code	Pac	ackage Description		Marketing Start Date		Marketing End Date	
1 NDC:59651-340- 01	100 in 1 BOTT Product	n 1 BOTTLE; Type 0: Not a Combination					
2 NDC:59651-340- 05	500 in 1 BOTT Product	0 in 1 BOTTLE; Type 0: Not a Combination 02/09/2023					
Marketing Information							
Marketing Category	Applicat	tion Number or Monog Citation	raph	Marketing Start Date		eting End Date	
ANDA	ANDA21396	7		02/09/2023			

Methocarbamol (UNII: 1250D7737X) (Methocarbamol - UNII:1250D7737X) Methocarbamol (Discrete Additional Additin Additional Additional Additional Additional Addi	METHOCAR methocarbamol t		ated							
Route of Administration ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strengt Strengt Methocarbamol (UNII: 1250D7737X) (Methocarbamol - UNII:1250D7737X) Methocarbamol Strengt Inactive Ingredients Ingredient Name Strengt Strengt STARCH, CORN (UNII: 08232NY35)) Ingredient Name Strengt MagNesium Steanate (UNII: 08230NY35) Methocarbamol Ingredient Name Strengt SOBIUM LAURYL SULFATE (UNII: 08280000) 0 0 0 0 Povidoone K30 (UNII: 07290W132X) 0 0 0 0 SODIUM LAURYL SULFATE (UNII: 36863141)) SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856)362A2) 0 0 0 SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856)362A2) Ingredient Name Size 19mm 19mm Flavor Imprint Code Mettrizzo 0 0 0 0 0 0 Packaging # Item Code Package Description Marketing Start Marketing E Date Date Date Date Date Date Date Date	Product Infor	mation								
Route of Administration ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength Methocarbamol (UNII: 1250D7737X) (Methocarbamol - UNII:1250D7737X) Methocarbamol - UNII:1250D7737X) Methocarbamol - UNII:1250D7737X) Inactive Ingredients Ingredient Name Strength STARCH, CORN (UNII: 08232NY35))	Product Type							59651-341		
Ingredient Name Basis of Strength Strength Methocarbamol (UNII: 1250D7737X) (Methocarbamol - UNII:1250D7737X) Methocarbamol 750 mg Inactive Ingredients Ingredient Name Streng STARCH, CORN (UNII: 08232NY35)) HYPROMELLOSE 2910 (6 MPA.65) (UNII: 0VZ 8WG20P6) Ingredient Name Streng STARCH, CORN (UNII: 08232NY35)) HYPROMELLOSE 2910 (6 MPA.65) (UNII: 0VZ 8WG20P6) Ingredient Name Streng Machesium StearAte (UNII: 0097M6130) POLYETHYLENE GLYCOL 400 (UNII: 86978945GQ) POLYETHYLENE GLYCOL 400 (UNII: 86978945GQ) Ingredient Name Ingredient Name SODIUM LAURYL SULFATE (UNII: 19750QY32X) SODIUM STARCH GLYCOLATE (UNII: 19750QY32X) Ingredient Name Ingredient Name Ingredient Name SODIUM STARCH GLYCOLATE (UNII: 15FIX9V2JP) Ingredient Name Ingredie		stration	ORAL							
Ingredient Name Basis of Strength Strength Methocarbamol (UNII: 1250D7737X) (Methocarbamol - UNII:1250D7737X) Methocarbamol 750 mg Inactive Ingredients Ingredient Name Streng STARCH, CORN (UNII: 08232N735)) HYPROMELLOSE 2910 (6 MPA.S) (UNII: 000230W350) Impredient Name Streng MAGNESIUM STEARATE (UNII: 70097MG130) POLYETHYLENE GLYCOL 400 (UNII: 150979345GQ) Impredient Name Impredient Name SODIUM LAURYL SULFATE (UNII: 366G85141) SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856)3G2A2) Impredient Name Impredient Name SODIUM LAURYL SULFATE (UNII: 366G85141) SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856)3G2A2) Imprint Code Impredient Name SoDIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856)3G2A2) Imprint Code Impredient Name Impredient Name SoDIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856)3G2A2) Imprint Code Impredient Name Impredient Name Product Characteristics Imprint Code METT;750 Impredient Name Imprint Code METT;750 Contains Imprint Code Marketing E Impredient Name Impredient Name Name 1 NDC:59651-341-										
Methocarbamol (UNII: 1250D7737X) (Methocarbamol - UNII: 1250D7737X) Methocarbamol (T50 mg Ingredient Name Streng STARCH, CORN (UNII: 08232NY35)) HYPROMELLOSE 2910 (6 MPA.S) (UNII: 0WZ 8WG20P6) MaGNESIUM STEARATE (UNII: 70097M6130) POLYETHYLENE GLYCOL 400 (UNII: 6978945GQ) POLYETHYLENE GLYCOL 400 (UNII: 6978945GQ) POLYETHYLENE GLYCOL 400 (UNII: 6978945GQ) POLYETHYLENE GLYCOL 400 (UNII: 686863141)) SODIUM STARCH GLYCOLATET (UNII: 368G85141)) SODIUM STARCH GLYCOLATET TYPE A POTATO (UNII: 5856)3GZA2) TALC (UNII: 75EV7J4RI) TITANIUM DIOXIDE (UNII: 15FIX9V2JP) Solute (Biconvex) Size POLYETHYLENE CLYCOL Solute (Biconvex) Size Imprint Code Marketing Start Marketing Start POLYETHYLENE CLYCOL OULE (Biconvex) Size Imprint Code POLYETHYLENE CLYCOL OULE (Biconvex)	Active Ingredi	ent/Active	Moiety							
Ingredient Name Streng Magnesium stearate (UNII: 00230W320) POVIDORE K30 (UNII: U725QW32X) Solum starch GLYCOLATE TYPE A POTATO (UNII: 5856)3G2A2) TALC (UNII: 75EV7J4RLU) Streng Streng Product Characteristics Color WHTE Score no score Shape CAPSULE (Biconvex) Size 19mm Flavor Contains Marketing Start Marketing E 100/1 Solid 1 BOTTLE; Type 0: Not a Combination 08/12/2020 08/12/2020 NDC:S9651-341- 100 in 1 BOTTLE; Type 0: Not a Combination 08/12/2020 08/12/2020 NDC:S9651-341- 500 in 1 BOTTLE; Type 0: Not a Combination 08/12/2020 > <tr< td=""><td></td><td>Ingre</td><td>edient Name</td><td></td><td></td><td>Basis of St</td><td>rength</td><th>Strength</th></tr<>		Ingre	edient Name			Basis of St	rength	Strength		
Ingredient Name Streng STARCH, CORN (UNII: 08232NY3SJ) HYPROMELLOSE 2910 (6 MPA.S) (UNII: 00/Z 8WG20P6) MAGNESIUM STEARATE (UNII: 70097M6/30) POLYETHYLENE GLYCOL 400 (UNII: 8697894SG0) POLYETHYLENE GLYCOL 400 (UNII: 8697894SG0) POLYETHYLENE GLYCOL 400 (UNII: 8697894SG0) SODIUM LAURYL SULFATE (UNII: 70097M6/130) SODIUM LAURYL SULFATE (UNII: 368G65141)) SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856/3G2A2) TALC (UNII: 75EV7/3R1U) SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856/3G2A2) POCUCE Char> VERTIFICA Sodium Starch GLYCOLATE TYPE A POTATO (UNII: 5856/3G2A2) TALC (UNII: 75EV7/3R1U) Sodium Starch GLYCOLATE TYPE A POTATO (UNII: 5856/3G2A2) VERTIFICA POCUCE Char> VERTIFICA Imprint Code METT: 750 Contains VERTIFIC TYPE 0: Not a Combination 08/12/2020 VERTIFIC: Type 0: Not a Combination 08/12/2020 <th colspan="2" n<="" td=""><td>Methocarbamol (U</td><td>INII: 1250D773</td><td>7X) (Methocarbamol - UNII:125</td><td>60D77</td><td>737X)</td><td>Methocarbamo</td><td>)I</td><th>750 mg</th></th>	<td>Methocarbamol (U</td> <td>INII: 1250D773</td> <td>7X) (Methocarbamol - UNII:125</td> <td>60D77</td> <td>737X)</td> <td>Methocarbamo</td> <td>)I</td> <th>750 mg</th>		Methocarbamol (U	INII: 1250D773	7X) (Methocarbamol - UNII:125	60D77	737X)	Methocarbamo)I	750 mg
STARCH, CORN (UNII: 08232NY35)) Image: Starch (CORN (UNII: 00232NY35)) Image: Starch (UNII: 002706130) HYPROMELLOSE 2910 (6 MPA.S) (UNII: 009706130) Image: Starch (UNII: 009706130) Image: Starch (UNII: 009706130) POLYETHYLENE GLYCOL 400 (UNII: B697894SGQ) Image: Starch (UNII: 00228W32X) Image: Starch (UNII: 00228W32X) SODIUM LAURYL SULFATE (UNII: 368GB5141]) Image: Starch (UNII: 55856)3G2A2) Image: Starch (UNII: 55856)3G2A2) TALC (UNII: 758V7)4R1U) Image: Starch (UNII: 15FIX9V2)P) Image: Starch (UNII: 15FIX9V2)P) Product Characteristics Color WHITE Score no score Shape CAPSULE (Biconvex) Size 19mm Flavor Imprint Code Marketing E Date V Product Product Marketing E Date 1 NDC:59651-341- 100 in 1 BOTTLE; Type 0: Not a Combination ol (08/12/2020) 08/12/2020 Imprint Code Imprint Code Imprint Code 1 NDC:59651-341- 100 in 1 BOTTLE; Type 0: Not a Combination ol (08/12/2020) 08/12/2020 Imprint Code Imprint Code Imprint Cols Imprint Cols Imprint Code Marketing E Imprint Code Imprint Code Im	Inactive Ingre	dients								
HYPROMELLOSE 2910 (6 MPA.S) (UNII: 0007M6I30) Image: Comparison of the co			-					Strength		
Magnesium stearate (UNII: 70097M6i30) Image: Stearate (UNII: 20097M6i30) Image: Stearate (UNII: 20097M6i30) POVYETHYLENE GLYCOL 400 (UNII: 86978945GQ) Image: Stearate (UNII: 275QV32X) Image: Stearate (UNII: 275QV32X) SOTUM LAURYL SULFATE (UNII: 3686B5141)) Image: Stearate (UNII: 75CV7)4R1U Image: Stearate (UNII: 75CV7)4R1U TITAL C (UNII: 75CV7)4R1U Image: Stearate (UNII: 15FIX9V2)P) Image: Stearate (UNII: 15FIX9V2)P) Vertice Charace resistics Contains CAPSULE (Biconvex) Size 19mm Flavor OB/C:59651-341- 100 in 1 BOTTLE; Type 0: Not a Combination of 0s/12/2020 NDC:59651-341- 500 in 1 BOTTLE; Type 0: Not a Combination of 0s/12/2020 NDC:59651-341- 500 in 1 BOTTLE; Type 0: Not a Combination of 0s/12/2020 NDC:59651-341- 500 in 1 BOTTLE; Type 0: Not a Combination of 0s/12/2020 OB/12/2020 NDC:59651-341- 500 in 1 BOTTLE; Type 0: Not a Combination of 0s/12/2020 OB/12/2020 NDC:59651-341- 500 in 1 BOTTLE; Type 0: Not a Combination of 0s/12/2020 OB/12/2020 NDC:59651-34			•							
PolyETHYLENE GLYCOL 400 (UNII: B697894SGQ) Image: Section 1000 (UNII: U725QWY32X) Image: Section 1000 (UNII: U725QWY32X) SODIUM LAURYL SULFATE (UNII: 368GB5141)) Image: Section 1000 (UNII: TSEV7)4RLU Image: Section 1000 (UNII: TSEV7)4RLU) SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856)3G2A2) Image: Section 1000 (UNII: TSEV7)4RLU) Image: Section 1000 (UNII: TSEV7)4RLU) TITANUM DIOXIDE (UNII: 15FIX9V2)P) Image: Section 1000 (UNII: 15FIX9V2)P) Image: Section 1000 (UNII: 15FIX9V2)P) Product Characteristics Score no score Shape CAPSULE (Biconvex) Size 19mm Flavor CAPSULE (Biconvex) Size 19mm Flavor Marketing Start Marketing E Voc.59651-341- 100 in 1 BOTTLE; Type 0: Not a Combination 1000 (B/12/2020) 08/12/2020 1////////////////////////////////////										
POVIDONE K30 (UNII: U725QWY32X) Image: Constant of the second of th										
SOUUM LAURYL SULFATE (UNII: 368GB5141)) SOUUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856)3G2A2) TALC (UNII: 75EV7)4R1U) TITANIUM DIOXIDE (UNII: 15FiX9V2)P) Product Characteristics Color WHITE Score 19mm Flavor CAPSULE (Biconvex) Size 19mm Flavor Contains METT; 750 Contains METT; 750 Product Characteristics Flavor Contains METT; 750 Product Characteristics Color WHITE Code METT; 750 Contains METT; 750 Contains METT; 750 Contains Code Company Methy Code Company Methy Code Company Code Code Code Code Code Code Code Code										
Solution Starch GLYCOLATE TYPE A POTATO (UNII: 5856/3G2A2) Image: Solution Starch GLYCOLATE TYPE A POTATO (UNII: 5856/3G2A2) TIAC (UNII: 7SEV7J4R1U) Titanium DIOXIDE (UNII: 15FIX9V2JP) Image: Solution Starch GLYCOLATE TYPE A POTATO (UNII: 5856/3G2A2) Product Charateristics Color WHITE Score no score Size 19mm Flavor GAPSULE (Biconvex) Size 19mm Flavor Mert;750 CAPSULE (Biconvex) Size 19mm Flavor Contains Mert;750 Product Marketing Start Marketing E Date Date NDC:59651-341: 100 in 1 BOTTLE; Type 0: Not a Combination or 80/12/2020 08/12/2020 Imprive Colspan="4">Imprive Colspan="4" Imprive Colspan=										
TIT Image: Second			· ·	~~ ^ ~ `						
TITANIUM DIOXIDE (UNII: 15FIX9V2JP) Marketing E PIOUCT Characteristics no score Shape CAPSULE (Biconvex) Size 19mm Flavor CAPSULE (Biconvex) Imprint Code METT;750 V V METT;750 METT;750 Product Code Metting Start Marketing E Date Date 1 NDC:59651-341- 100 in 1 BOTTLE; Type 0: Not a Combination of 08/12/2020 08/12/2020 2 NDC:59651-341- 500 in 1 BOTTLE; Type 0: Not a Combination of 08/12/2020 08/12/2020 NDC:59651-341- 500 in 1 BOTTLE; Type 0: Not a Combination of 08/12/2020 08/12/2020 Marketing E Marketing Information Marketing Category Application Number or Monograph Date Marketing Start Date Marketing E				נצאצנ)						
Product Characteristics Shape Score no score Shape CAPSULE (Biconvex) Size 19mm Imprint Code METT;750 Contains Marketing Start Marketing E Marketing Start Marketing E Date 08/12/2020 Marketing Start Marketing E Date Marketing Start Marketing E Date 08/12/2020 Marketing Information Marketing Start Marketing E Marketing Start Marketing E Marketing Start Marketing E			חוכ							
Color WHITE Score no score Sh→pe CAPSULE (Biconvex) Size 19mm Harror Imprint Code METT;750 Contains Marketing Start Marketing E Marketing Category 100 in 1 BOTTLE; Type 0: Not a Combination product 08/12/2020 NDC:59651-341- 100 in 1 BOTTLE; Type 0: Not a Combination product 08/12/2020 NDC:59651-341- 500 in 1 BOTTLE; Type 0: Not a Combination product 08/12/2020 Marketing Category Application Number or Monograph Marketing Start Date Marketing Start Date										
Shape CAPSULE (Biconvex) Size 19mm Flavor Imprint Code METT;750 Contains Marketing Start Marketing E # Item Code Package Description Marketing Start Marketing E 1 NDC:59651-341- 100 in 1 BOTTLE; Type 0: Not a Combination Product 08/12/2020 Marketing E 2 NDC:59651-341- 500 in 1 BOTTLE; Type 0: Not a Combination Product 08/12/2020 Marketing E MDC:59651-341- 500 in 1 BOTTLE; Type 0: Not a Combination Product 08/12/2020 Marketing E Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing E	Product Chara	acteristics								
File Import Code METT;750 Voltarians Metti;750 Package Description Marketing Start Date Marketing E Date 1 NDC:59651-341- 100 in 1 BOTTLE; Type 0: Not a Combination Product 08/12/2020 08/12/2020 2 NDC:59651-341- 500 in 1 BOTTLE; Type 0: Not a Combination Product 08/12/2020 08/12/2020 2 NDC:59651-341- 500 in 1 BOTTLE; Type 0: Not a Combination Product 08/12/2020 08/12/2020 2 NDC:59651-341- 500 in 1 BOTTLE; Type 0: Not a Combination Product 08/12/2020 08/12/2020 2 NDC:59651-341- 500 in 1 BOTTLE; Type 0: Not a Combination Product 08/12/2020 Marketing E Date 3 NDC:59651-341- 500 in 1 BOTTLE; Type 0: Not a Combination Product 08/12/2020 08/12/2020 4 NDC:59651-341- 500 in 1 BOTTLE; Type 0: Not a Combination Product 08/12/2020 08/12/2020 5 NDC:59651-341- 500 in 1 BOTTLE; Type 0: Not a Combination Product 08/12/2020 08/12/2020 6 Notestage Notestage Notestage Notestage 7 Notestage Notestage Notestage Notestage	Color	WHITE		Sco	re		no sco	no score		
Marketing Category Marketing Start Date Marketing Category Modicinal BOTTLE; Type 0: Not a Combination Product 08/12/2020 Marketing E Date Marketing Category S00 in 1 BOTTLE; Type 0: Not a Combination Product 08/12/2020 08/12/2020 Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing E Date	Shape	CAPSULE (E	Biconvex)	Size)		19mm			
Marketing Start Date # Item Code Package Description Marketing Start Date Marketing E Date 1 NDC:59651-341- 100 in 1 BOTTLE; Type 0: Not a Combination Product 08/12/2020 08/12/2020 2 NDC:59651-341- 500 in 1 BOTTLE; Type 0: Not a Combination Product 08/12/2020 08/12/2020 Hereing Category Application Number or Monograph Citation Marketing Start Date Marketing E Date	Flavor			Imp	rint Code	1	METT;750			
# Item Code Package Description Marketing Start Date Marketing E Date 1 NDC:59651-341- 01 100 in 1 BOTTLE; Type 0: Not a Combination Product 08/12/2020 08/12/2020 2 NDC:59651-341- 05 500 in 1 BOTTLE; Type 0: Not a Combination Product 08/12/2020 08/12/2020 Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing E Marketing E										
# Item Code Package Description Marketing Start Date Marketing E Date 1 NDC:59651-341- 01 100 in 1 BOTTLE; Type 0: Not a Combination Product 08/12/2020 08/12/2020 2 NDC:59651-341- 05 500 in 1 BOTTLE; Type 0: Not a Combination Product 08/12/2020 08/12/2020 Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing E Marketing E	Packaging									
1 NDC:59651-341- 01 100 in 1 BOTTLE; Type 0: Not a Combination Product 08/12/2020 2 NDC:59651-341- 05 500 in 1 BOTTLE; Type 0: Not a Combination Product 08/12/2020 Marketing Category Marketing Start Date		Pac	Package Description			-				
2 05 Product 06/12/2020 Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing Endet			LE; Type 0: Not a Combination	ation			ale			
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing E Date	2 NDC:59651-341-	500 in 1 BOTT	LE; Type 0: Not a Combination	Combination 08/12/2020						
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing E Date										
Category Citation Date Date	Marketing	Informat	ion							
		Applicat		ph				rketing End Date		
ANDA ANDA213967 08/12/2020	ANDA	ANDA21396	7		08/12/2020					

Labeler - Aurobindo Pharma Limited (650082092)

Establishment	t		
Name	Address	ID/FEI	Business Operations
APL HEALTHCARE LIMITED		650918514	ANALYSIS(59651-340, 59651-341), MANUFACTURE(59651-340, 59651-341)

Revised: 1/2024

Aurobindo Pharma Limited